News

AB-Therapeutics Hires José Alfón as Director of Development

Alfón, previously at Palau Pharma, will head the Catalan company’s R&D

January 3, 2011

The Catalan biotechnology company AB-Therapeutics, that focuses on drug development, has just hired José Alfón as Director of Development. Alfón previously served as Drug Development Project Leader at Palau Pharma.

In bringing Alfón aboard, AB-Therapeutics has finished putting together a solid team of scientists with broad international experience. His mission will be to direct the company’s recently begun preclinical development program for an anti-cancer drug candidate through the clinical phase.

José Alfón, 43, earned a Bachelor of Pharmacy and an MS in Pharmaceutical Sciences from the Hebrew University of Jerusalem, and a PhD in Pharmaceutical Sciences from the University of Barcelona (UB). He has over ten years experience in identifying drug candidates and in developing drugs from the discovery stage to Phase II clinical trials. In addition to Palau Pharma, where has spent most of his career to date, he has also held various research positions at the Hebrew University of Jerusalem, the Spanish National Research Council (CSIC), and different hospitals in the UK and Israel.

ABOUT AB-THERAPEUTICS

AB-Therapeutics, SL is a drug discovery and development company headquartered in Barcelona, Catalonia, Spain, with planned US facilities in Boston. The company was cofounded in late 2009 by AB Biotics, SA, a company publicly traded at the Spanish alternative stock market (MAB), Carles Domenech (CEO) and Jordi Espadaler (VP Discovery Research).

AB-Therapeutics, SL develops safer human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. It has a molecule ready to start preclinical development in 4Q2010, with Phase I clinical trials (first in man) starting in late 2011 / early 2012. A second drug candidate will start preclinical development in 2Q2011.

Contact:
 
Media relations:
Nuria Peláez
Tel. +34 902 903 844
media.relations@ab-therapeutics.com
 
Investors:
Carles Domènech, PhD
Tel. +34 935 868 977
contact@ab-therapeutics.com

LATEST NEWS

05.12.2018

News

AbilityPharma ha superado el millón de euros en la ronda de crowdfunding que abrió el pasado mes de septiembre + info
07.11.2018

News

Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Biliary Tract Cancer + info
19.09.2018

News

Ability Pharmaceuticals anuncia la inclusión del primer paciente en el estudio clínico de la fase 2 de ABTL0812 en Francia + info
24.08.2018

News

At AbilityPharma we are very pleased to announce the start of a crowdfunding campaign through de Capital Cell + info
19.02.2018

News

AbilityPharma Announces FDA Approval of Phase 1/2 Trial of ABTL0812 for Patients with Advanced Metastatic Pancreatic Cancer + info
13.12.2017

News

AbilityPharma Announces FDA Approval of IND for Phase 2 Trial of ABTL0812 in Patients with Endometrial Cancer or Squamous Non-Small Cell Lung Cancer + info
05.10.2017

News

Ability Pharmaceuticals announces the approval from the French Medicines Agency ANSM to initiate a Phase 1/2a Clinical Trial with ABTL0812 to treat patients with endometrial cancer or squamous lung cancer as first-line therapy in France + info
18.09.2017

News

Ability Pharmaceuticals Announces EMA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info
07.03.2017

News

Ability Pharma sponsors the 37th National Meeting of the Spanish Society of Pharmacology + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG